No staff cut backs at Montrose, according to this recent story....GSK surprising guided same vaccine sales in 2010, as 2009. Roche confirmed no cut backs of Tamiflu orders in 2010.
--
In would seem the market is of a view that production of Relenza will decline....but doing all this research seems to indicate otherwise.
Just the sort of stock you want to own...into surprisingly positive news flow.
Swine flu boosts Glaxos profits GLAXOSMITHKLINE HAS reported that its fourth-quarter profit soared by 66%, boosted by strong sales of swine flu vaccine and flu medicine.
.........
The company said it aimed to cut expenditure by 500m by 2012, but said it would not announce a target for job reductions. Published reports have said that about 4000 of GlaxoSmith-Klines 99,000 employees worldwide might be affected.
-----
There was good news for the workforce at Glaxos Montrose site yesterday when Angus MP Mike Weir said he had received an assurance that the Montrose facility would not be affected by the restructuring proposals.
There has been some concern locally that the site could be affected since rumours of the changes began circulating, said Mr Weir.
The Montrose site remains a vital part of our local economy. Although it has had its ups and downs over the last few years its future now seems assured.
The recent investment in the site and the opening, by the First Minister, of the extension shows that the company continues to view Montrose as an integral part of its future strategy.
The Montrose site produces six active pharmaceutical ingredients for GSKs respiratory and HIV business.
The site is also the only one in the world licensed to manufacture the anti-flu drug zanamivir of which there has been a doubling of output as health agencies around the world stockpile treatments to combat swine flu.
BTA Price at posting:
$2.04 Sentiment: Buy Disclosure: Held
